Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.

Autor:	Charliński G; Department of Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.; Department of Hematology, Nicolaus Copernicus Hospital, Torun, Poland., Grząśko N; Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland., Bołkun Ł; Department of Hematology, Medical University in Białystok, Białystok, Poland., Sawicki W; Department of Internal Medicine and Hematology, Military Institute of Medicine, Warsaw, Poland., Paczkowska E; Department of General Pathology, Pomeranian Medical University, Szczecin, Poland., Druzd-Sitek A; Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Usnarska-Zubkiewicz L; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University, Wroclaw, Poland., Butrym A; Department of Cancer Prevention and Therapy, Wroclaw Medical University, Wroclaw, Poland., Wiater E; Department of Hematology, Nicolaus Copernicus Hospital, Torun, Poland., Boguradzki P; Department of Haematology, Transplantology, and Internal Diseases, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland., Budziszewska B; Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Wojciechowska M; Department of Hematology, Specialist District Hospital, Olsztyn, Poland., Mordak-Domagała M; Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland., Jurczyszyn A; Department of Haematology, Faculty of Medicine, Plasma Cell Dyscrasias Center, Jagiellonian University, Kraków, Poland.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Oct; Vol. 30 (7), pp. 1144-1151. Date of Electronic Publication: 2023 Sep 20.
DOI:	10.1177/10781552231203371
Abstrakt:	Introduction: Therapeutic adherence (TA) is one of the most important factors influencing the effectiveness of treatment. Oral anti-cancer drugs are increasingly used to treat malignancy including multiple myeloma (MM). Our study aimed to determine TA of patients with MM treated with IMiDs, to identify TA risk factors, and to determine satisfaction with medical care during the treatment with IMiDs. Methods: A cross-sectional survey-based study involving adult patients with MM treated with IMiDs. Results: Between January 2021 and May 2021, 267 patients with MM were enrolled in the study. The dosing schedule was declared as easy by 71.8% of patients, as standard for 24.0%, and difficult for 4.2% of patients. During MM treatment, 85.0% of patients did not skip any IMiDs dose, and 87.6% did not skip the IMiDs dose in the last cycle of chemotherapy. Identified factors affecting TA included the treatment duration and education level. In addition, depending on the patient's well-being, gender, and household companionship influenced TA. Satisfaction with medical care during the treatment with IMiDs was declared by 95.5% of patients with MM. In our cohort, 95.5% of patients were satisfied with the information they received from the hematologist during treatment with IMiDs. Conclusions: Patients with MM treated with IMiDs are highly adherent to treatment. With time from the beginning of treatment, patients need more attention and motivation to adhere to the therapy rules. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu